Drug
Experimental Chf6001 3200 G
Experimental Chf6001 3200 G: highest development phase Phase 2, developed by Chiesi Farmaceutici. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Chiesi Farmaceutici
Trials
| Drug | Phase | Indication |
|---|---|---|
| Experimental: CHF6001 3200 μg NCT06029595 | Phase 2 | Uncontrolled Asthma |
Latest
No recent events.
Follow Experimental Chf6001 3200 G on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.